Dermatophyte infections

Trichophyton indotineae Infection, São Paulo, Brazil, 2024

mycolabadmin

A businessman from São Paulo, Brazil contracted a difficult-to-treat fungal skin infection caused by Trichophyton indotineae, which is resistant to the common antifungal drug terbinafine. After terbinafine failed to help over 9 weeks, doctors switched him to itraconazole, which worked well after 8 weeks. Genetic testing showed his fungal strain had a specific resistance mutation and was most similar to a strain from Germany, suggesting he may have caught it while traveling in Europe.

Synthesis, Physicochemical Properties and Anti-Fungal Activities of New Meso-Arylporphyrins

mycolabadmin

Researchers created three new porphyrin compounds that effectively kill fungal infections like Candida and athlete’s foot fungi. These compounds can also generate singlet oxygen when exposed to light, making them potentially useful for photodynamic therapy treatments. Testing showed they inhibited fungal growth at relatively low concentrations, suggesting they could become new antifungal medications.

Spread of Antifungal-Resistant Trichophyton indotineae, United Kingdom, 2017–2024

mycolabadmin

A dangerous fungal infection called Trichophyton indotineae is rapidly spreading across the United Kingdom, particularly among people with connections to South Asia. This infection causes stubborn skin rashes that don’t respond well to common antifungal treatments like terbinafine. The number of cases has skyrocketed, making up 38% of all dermatophyte infections by 2024, and doctors need to be aware of this emerging threat.

Characterization of Biofilm Formation by the Dermatophyte Nannizzia gypsea

mycolabadmin

This research studies how a fungus called Nannizzia gypsea forms protective biofilms on skin and hair, making infections harder to treat. Scientists grew the fungus in the lab and on real human hair, discovering it creates thick slime-like protective layers containing proteins, sugars, and DNA. The fungus also produces enzymes that break down keratin (the main protein in skin and hair) and activates drug-pumping proteins that help it resist antifungal medications. Understanding these defense mechanisms could help develop better treatments for fungal skin infections that are currently difficult to cure.

Unmasking Tinea Incognito: Case Study, Insights Into the Pathogenesis, and Recommendations

mycolabadmin

A 29-year-old woman was incorrectly treated for psoriasis with steroids, which made her fungal infection worse instead of better. When doctors finally diagnosed her with a fungal infection (tinea incognito), they found it was caused by a common dermatophyte fungus. This case highlights how steroid creams can hide fungal infections and make them spread, and shows why recognizing this condition is important for proper treatment.

Treatment and diagnostic challenges associated with the novel and rapidly emerging antifungal-resistant dermatophyte, Trichophyton indotineae

mycolabadmin

A new type of fungal infection called Trichophyton indotineae has emerged and spread globally, particularly from India. It causes widespread skin infections that are difficult to treat because the fungus resists common antifungal medications. Doctors and laboratories need to be aware of this infection to properly identify it and choose effective treatments, especially for patients with travel history to affected regions.

Synergistic effects of Cyp51 isozyme-specific azole antifungal agents on fungi with multiple cyp51 isozyme genes

mycolabadmin

This study found that different azole antifungal drugs work better against different versions of an enzyme (Cyp51) that fungi need to survive. By combining two azole drugs that each target different enzyme versions, researchers achieved stronger antifungal effects than either drug alone. This discovery suggests a new strategy for treating stubborn fungal infections by carefully selecting drug combinations based on which enzyme versions the fungus possesses.

Safety and Efficacy of a 48-Month Efinaconazole 10% Solution Treatment/Maintenance Regimen: 24-Month Daily Use Followed by 24-Month Intermittent Use

mycolabadmin

Researchers studied a 4-year treatment plan for toenail fungal infections using efinaconazole, an antifungal solution applied daily for 2 years, then 2-3 times weekly for another 2 years. The treatment was safe and effective, with all patients who achieved a cure maintaining it through the maintenance phase, and even some non-cured patients improving further. The study included many elderly patients, showing the treatment is safe across all age groups and could help prevent infection relapse.

In vitro characterization of Trichophyton rubrum biofilm by combined anti-biofilm enzymes

mycolabadmin

Athlete’s foot and nail fungal infections caused by Trichophyton rubrum are difficult to treat because the fungus forms protective biofilms that resist antifungal medications. This research shows that enzymes like cellulase, protease, and amylase can break down these biofilm barriers when used alone or in combination. The combination approach was most effective, suggesting that enzyme-based treatments could become useful additions to current fungal infection therapies.

Research Topic: Dermatophyte infections